Loading stock data…
ALVO
$4.16-0.08 (-1.89%)
After Hours$4.12-0.04 (-0.96%)· Last close Jun 9
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alvotech in the Healthcare sector is trading at $4.16 with a market capitalization of $1.3B. Wall Street consensus targets $13.83 (6 analysts), implying a +232.5% move over the next 12 months. The stock is currently near its 52-week low of $2.94, remaining 21.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +232.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.16
Potential Downside
60.2%
Whystock Fair Value$1.65
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$13.83+232.5%
Range$4.00 – $50.00
Fundamentals
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.30B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
41.60
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.81%
Volume
Today's trading volume
1.42M
Recent News
Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO)
Alvotech (NASDAQ:ALVO) shares climbed 12% in premarket trading on Thursday after the biotechnology company announced that the U. S.
How The Investment Story For Alvotech (ALVO) Is Shifting Without New Analyst Guidance
Alvotech’s latest analyst update comes with no change in the price target, keeping expectations steady for now. Even without fresh commentary or revised models, that unchanged target still sends a signal about how analysts are currently framing the stock. Read on to see what this means for your watchlist and how to track shifts in the narrative as new information comes through. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value...
Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection
Alvotech (NASDAQ:ALVO) is one of the most promising penny stocks according to Wall Street analysts. On May 11, Alvotech announced the completion of a routine FDA surveillance inspection at its manufacturing facility in Reykjavik, Iceland. While the FDA issued a Form 483 at the conclusion of the visit on May 8, 2026, the company stated […]
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global Healthcare Conference in New York. Speaking with Jefferies analyst Marco Baruzzi, Wessman said Alvotech ha